95 completed, 35 recruiting, 30 terminated, 17 active not recruiting. 199 Phase 1, 66 Phase 2.
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 27 | 2027-02-01 | 2026-11-02 |
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation gecacitinib Hydrochloride Tablets - Myeloid Neoplasms With Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 10 | 2026-10-15 | 2026-10-28 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs) | Phase 1 | Recruiting | Damora Therapeutics | 250 | 2026-09-01 | 2026-10-27 |
| Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis ropeginterferon alfa- 2b, Ruxolitinib - Myelofibrosis | Phase 1 | Recruiting | University of Utah | 15 | 2026-08-21 | 2026-10-19 |
| QT Interval/Corrected QT Interval (QT/QTc) Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants TQ05105 tablets, Placebo tablets, Moxifloxacin Hydrochloride Tablets - Myelofibrosis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2026-07-30 | 2026-08-07 |
| TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT Tacrolimus, Early Tacrolimus Taper Strategy - GVHD, Hematopoietic Cell Transplantation (HCT) | Phase 1 | Recruiting | Stanford University | 50 | 2026-07-21 | 2026-08-17 |
| Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets TQ05105 tablets, Rabeprazole sodium enteric-coated tablets - Myelofibrosis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 17 | 2026-07-20 | 2026-07-27 |
| Study of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic Disorders ZE74-0282 - Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Recruiting | Eilean Therapeutics | 60 | 2026-06-01 | 2026-11-12 |
| A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis rebecsinib - Secondary AML, Myelofibrosis | Phase 1 | Recruiting | Aspera Biomedicines, Inc. | 28 | 2026-05-21 | 2026-07-20 |
| Therapeutic RSK1 Targeting in Myeloid Malignancies PMD-026 - Myeloid Malignancy | Phase 1 | Recruiting | Washington University School of Medicine | 30 | 2026-05-20 | 2026-10-21 |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 218 | 2026-05-11 | 2026-11-13 |
| A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms PRT12396 - Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Recruiting | Prelude Therapeutics Incorporated | 100 | 2026-04-29 | 2026-10-29 |
| Safety and Tolerability of ZE74-0282 in Healthy Volunteers ZE74-0282-0001 or placebo - Healthy Volunteers | Phase 1 | Recruiting | Eilean Therapeutics AU Pty Ltd | 64 | 2026-04-16 | 2026-07-28 |
| Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis Pelabresib, Ruxolitinib - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 3 | 2026-04-15 | 2026-09-09 |
| To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects TQ05105 - Myelofibrosis | Phase 1 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 24 | 2026-04-01 | 2026-04-06 |
| Momelotinib During and After HCT in Myelofibrosis Momelotinib - Myelofibrosis, Hematopoietic Cell Transplantation (HCT) | Phase 1 | Recruiting | Massachusetts General Hospital | 28 | 2026-02-23 | 2026-03-31 |
| Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) Axatilimab (SNDX-6352), Ruxolitinib - Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML) | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 66 | 2026-01-02 | 2026-10-09 |
| A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors Roginolisib - Myelofibrosis (MF) | Phase 1 / Phase 2 | Recruiting | iOnctura | 26 | 2025-11-17 | 2026-06-23 |
Showing 20 of 199. Sign in to see all of them.
Myeloproliferative Disorders (87) · Leukemia, Myeloid, Acute (76) · Myelodysplastic Syndromes (69) · Thrombocythemia, Essential (61) · Leukemia, Myelomonocytic, Chronic (60) · Polycythemia Vera (60) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (59) · Leukemia, Lymphocytic, Chronic, B-Cell (54) · Lymphoma, Non-Hodgkin (48) · Multiple Myeloma (48) · Leukemia (47) · Hodgkin Disease (42) · Lymphoma, Follicular (41) · Lymphoma, Large B-Cell, Diffuse (41)
Hemic and Lymphatic Diseases (199) · Bone Marrow Diseases (194) · Hematologic Diseases (193) · Neoplasms (117) · Myeloproliferative Disorders (112) · Neoplasms by Histologic Type (101) · Leukemia, Myeloid (94) · Pathologic Processes (89) · Pathological Conditions, Signs and Symptoms (89) · Disease Attributes (88) · Chronic Disease (86) · Neoplasms by Site (86) · Hemorrhagic Disorders (84) · Immune System Diseases (74) · Immunoproliferative Disorders (73)
ruxolitinib (43) · fludarabine phosphate (15) · Cyclophosphamide (13) · Peripheral Blood Stem Cell Transplantation (12) · Tacrolimus (11) · Busulfan (10) · Azacitidine (9) · Filgrastim (8) · Methotrexate (7) · Mycophenolic Acid (7) · Sirolimus (7) · Whole-Body Irradiation (7) · fludarabine (7) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (6) · Cyclosporine (6)
Incyte Corporation (12) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (9) · M.D. Anderson Cancer Center (8) · National Cancer Institute (NCI) (7) · Novartis Pharmaceuticals (7) · City of Hope Medical Center (6) · Case Comprehensive Cancer Center (4) · John Mascarenhas (4) · AbbVie (3) · Bristol-Myers Squibb (3) · Fred Hutchinson Cancer Center (3) · Mayo Clinic (3) · Northwestern University (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (3)
United States (156) · Italy (27) · Germany (24) · Australia (21) · France (21) · United Kingdom (18) · Canada (17) · Spain (16) · China (15) · Belgium (8) · Japan (8) · Netherlands (8) · South Korea (8) · Poland (6) · Bulgaria (4)
Ayalew Tefferi, MD (5) · Ronald Hoffman, MD (5) · John Mascarenhas, MD (4) · Fred Zheng, M.D. (2) · Haris Ali (2) · Jorge Cortes, MD (2) · Kenneth G. Lucas, MD (2) · Kyoo H. Lee, MD (2) · Martha Wadleigh, MD (2) · Richard K. Burt, MD (2) · Ruben Mesa, MD (2)
PMID 31527168, PMID 15570084, PMID 17562873, PMID 20843246, PMID 21742281, PMID 22259028, PMID 22547163, PMID 22718840, PMID 23682558, PMID 23993427, PMID 24002496, PMID 24355079, PMID 24474568, PMID 24530972, PMID 25563429, PMID 25762180, PMID 26210442, PMID 26853648, PMID 27479177, PMID 27634203, PMID 27736729, PMID 27931243, PMID 28934680, PMID 29515114, PMID 29544547, PMID 30249277, PMID 30562587, PMID 31778911, PMID 32325461, PMID 32396615, PMID 32634234, PMID 33635333, PMID 33718228, PMID 34581764, PMID 36105914, PMID 36125208, PMID 36594185, PMID 36881782, PMID 37290996, PMID 37422688, PMID 37530627, PMID 38118249, PMID 38259250, PMID 39863139, PMID 39924599, PMID 40241543, PMID 40334082, PMID 40643151, PMID 40752760, PMID 40919483
2018 (3), 2019 (3), P01CA108671 (3), P30CA033572 (3), 2017 (2), 2023 (2), P30CA006973 (2), P30CA015083 (2), U01CA062491 (2), 2014 (1), 2015 (1), 2025 (1), P01CA015396 (1), P01CA229092 (1), P30CA014599 (1)